Search

Your search keyword '"Fernandez Clotet, A."' showing total 27 results
Start Over Author "Fernandez Clotet, A." Search Limiters Full Text
27 results on '"Fernandez Clotet, A."'

1. Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn’s Disease

Author

Revés, Joana, Fernandez-Clotet, Agnes, Ordás, Ingrid, Buisson, Anthony, Bazoge, Maëva, Hordonneau, Constance, Ellul, Pierre, D’Anastasi, Melvin, Elorza, Ainara, Aduna, Marta, Rodríguez-Lago, Iago, Lajas, Inês Sousa, Raimundo, Ana, Bettencourt, Paulo J.G., Freire, Gonçalo, Sousa, Pedro, Primitivo, Ana, Delgado, Ivo, Rimola, Jordi, and Torres, Joana

Published
2024
Full Text
View/download PDF

2. Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis

Author

Maria Gonzalez-Vivo, Minna K. Lund Tiirikainen, Montserrat Andreu, Agnes Fernandez-Clotet, Alicia López-García, Francisca Murciano Gonzalo, Lourdes Abril Rodriguez, Carmen de Jesús-Gil, Ester Ruiz-Romeu, Lídia Sans-de San Nicolàs, Lluis F. Santamaria-Babí, and Lucía Márquez-Mosquera

Subjects
inflammatory bowel disease, ulcerative colitis, biological therapy, integrins, T lymphocytes, Medicine (General), R5-920
Abstract

BackgroundVedolizumab is a humanized monoclonal antibody targeting the α4β7 integrin used for the treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim of this work was to assess whether baseline circulating CD4+ and CD8+ memory T-lymphocyte subpopulations could help to identify patients with response to vedolizumab treatment in ulcerative colitis.MethodsProspective pilot study in 15 patients with active ulcerative colitis and previous failure to anti-TNFα starting vedolizumab treatment. Peripheral blood samples were obtained before the first dose of vedolizumab and at week 6 and 14 of treatment. Clinical remission was defined as a Mayo Clinic partial score of ≤2 points without any concomitant dose of steroids. Biochemical remission or endoscopic improvement was defined as fecal calprotectin

Published
2022
Full Text
View/download PDF

4. Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis

Author

Gonzalez-Vivo, Maria, primary, Lund Tiirikainen, Minna K., additional, Andreu, Montserrat, additional, Fernandez-Clotet, Agnes, additional, López-García, Alicia, additional, Murciano Gonzalo, Francisca, additional, Abril Rodriguez, Lourdes, additional, de Jesús-Gil, Carmen, additional, Ruiz-Romeu, Ester, additional, Sans-de San Nicolàs, Lídia, additional, Santamaria-Babí, Lluis F., additional, and Márquez-Mosquera, Lucía, additional

Published
2022
Full Text
View/download PDF

5. Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

Author

Garcia, MJ, Rivero, M, Fernandez-Clotet, A, de Francisco, R, Sicilia, B, Mesonero, F, de Castro, ML, Casanova, MJ, Bertoletti, F, Alonso, FJG, Garcia, AL, Julian, B, Calvet, X, Acosta, MBD, Jara, L, Varela, P, Nunez, A, Ricart, E, Riestra, S, Arias, L, Rodriguez, M, Arranz, L, Pajares, R, Mena, R, Calafat, M, Camo, P, Jimenez, L, Ponferrada, A, Madrigal, RE, Llao, J, Sese, E, Almela, P, Codesido, L, de la Maza, S, Leal, C, Sanchez, E, Marino, JRP, Domenech, E, Chaparro, M, and Gisbert, JP

Published
2022

6. Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study

Author

Ballester M, Mesonero F, Florez-Diez P, Gomez C, Fuentes-Valenzuela E, Martin N, Senosiain C, Vela M, Fernandez-Clotet A, Perez P, de Celix C, Calvino-Suarez C, Hermida B, Munoz R, Gonzalez-Vivo M, Brunet E, Jimenez N, Botella B, Yebra J, Suarez-Ferrer C, Bouhmidi A, Lopez-Serrano A, Ponferrada A, Duenas C, and Minguez M

Subjects
Adult, Cohort Studies, Young Adult, Hepatology, Risk Factors, Gastroenterology, Humans, Pharmacology (medical), Colitis, Ulcerative, Colonoscopy, Middle Aged, Colorectal Neoplasms, Inflammatory Bowel Diseases
Abstract

Background and Aims Patients with colonic inflammatory bowel disease (IBD) have a high risk of colorectal cancer (CRC). Current guidelines recommend endoscopic surveillance, yet epidemiological studies show poor compliance. The aims of our study were to analyse adherence to endoscopic surveillance, its impact on advanced colorectal lesions, and risk factors of non-adherence. Methods A retrospective multicentre study of IBD patients with criteria for CRC surveillance, diagnosed between 2005 and 2008 and followed up to 2020, was performed. Following European guidelines, patients were stratified into risk groups and adherence was considered when surveillance was performed according to the recommendations (+/- 1 year). Cox-proportional regression analyses were used to compare the risk of lesions. p-values below 0.05 were considered significant. Results A total of 1031 patients (732 ulcerative colitis, 259 Crohn's disease and 40 indeterminate colitis; mean age of 36 +/- 15 years) were recruited from 25 Spanish centres. Endoscopic screening was performed in 86% of cases. Adherence to guidelines was 27% (95% confidence interval, CI = 24-29). Advanced lesions and CRC were detected in 38 (4%) and 7 (0.7%) patients respectively. Adherence was associated with increased detection of advanced lesions (HR = 3.59; 95% CI = 1.3-10.1; p = 0.016). Risk of delay or non-performance of endoscopic follow-up was higher as risk groups increased (OR = 3.524; 95% CI = 2.462-5.044; p p < 0.001 for intermediate- and high- vs low-risk groups). Conclusions Adherence to endoscopic surveillance allows earlier detection of advanced lesions but is low. Groups at higher risk of CRC are associated with lower adherence.

Published
2022

7. P523 Effectiveness of biological treatments for inflammatory bowel disease in the elderly patients

Author

C J Suarez Ferrer, F Mesonero, B Caballol, M P Ballester, I Baston Rey, A Castaño Garcia, J Miranda Bautista, R Saiz Chumillas, J M Benitez, L Sanchez Delgado, A Lopez-Garcia, C Rubin de Celix, M D Martin-Arranz, A Lopez Sanroman, A Fernandez-Clotet, V Merino Murgui, C Calviño Suarez, P Florez, M E Lobato Matilla, B Sicilia, P Soto Escribano, C Maroto Martin, I Alonso Abreu, L Melcarne, P G Elena, E Iyo, A Elosua Gonzalez, E Saiz, L Hernandez Villalba, P Perez Galindo, L Torrealba Medina, S Monsalve Alonso, J A Olmos Jerez, C Dueñas Sadornil, and M Barreiro-De Acosta

Subjects
Gastroenterology, General Medicine
Abstract

Background Biological treatments used for the treatment of inflammatory bowel disease (IBD) have demonstrated their efficacy and safety, although these results were obtained from studies that mostly include young people generally included in clinical trials. The objective of our study is to assess the efficacy of these treatments in the elderly population in real life Methods Patients have been retrospectively included with established diagnosis of IBD aged 65 years or older at the time of initiating biological treatment(Infliximab, Adalimumab, Golimumab, Ustekinumab or Vedolizumab).Among the patients included, the clinical response (at the discretion of the researcher)after induction(around 12 weeks of treatment)and at 52 weeks was assessed.When that were available, the data related to endoscopic response at week 52 were collected(endoscopic activity was classified as moderate, mild or severe, according to the researcher) Results A total of 1090 patients were included(707 CD and 383 UC).The indication for biologic in our experience was lack of response to immunosuppressants(292, 27.1%), corticodependence(318, 29.5%), perianal disease(31, 2.9%), treatment for postoperative recurrence(76, 7.0%), severe corticorefractory ulcerative colitis(59, 5.5%), others(303, 28.1%).After induction, at approximately 12–14 weeks of treatment, 419(39.6%) were in clinical remission, 502(47.4%) had a response without remission, and 137 patients(12.9%) had no response.The percentages of remission with the different biologics were: infliximab 159 patients(42.6%), adalimumab 118 patients (38.4%), golimumab 9 patients(32.1%), ustekinumab 50(32.7%), vedolizumab 84(40.6%)(p = 0.3).At 52 weeks of treatment 442 patients(50.63%) clinical remission, 249 patients had a response (28.5%) and 53 patients had no response (6.1%). Before one year of treatment, 129 patients(14.8%) had suspended treatment due to ineffectiveness, being significantly higher(p Conclusion Biological drugs have response rates in elderly patients similar to those described in the general population. In our experience, golimumab was the drug that had to be discontinued most frequently due to ineffectiveness.

Published
2022
Full Text
View/download PDF

8. effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of Geteccu

Author

Ferrer, CJS, Mesonero, F, Caballol, B, Chumillas, RS, Baston-Reys, I, de Celix, CR, Meicarne, L, Marcos, AC, Calafat, M, Galan, HA, Villaamil, PV, Senosiain, BC, Diaz, CYR, Santos, RP, Cami, MM, Grau, MCR, Ramirez, F, Lopez-Garcia, A, Pastrana, BG, Partida, IG, Mateu, BB, del Campo, LC, Pena, EG, Iyo, E, Gonzalez, AE, Sainz, E, Hernandez, L, Galindo, PP, Garcia, MJR, Martin-Arranz, MD, Sanroman, AL, Fernandez-Clotet, A, Sicilia, B, Suarez, CC, Ciria, MM, and Barreiro-De Acosta, N

Published
2021

9. Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry

Author

Chaparro, Maria, Garre, Ana, Iborra, Marisa, Sierra, Monica, Barreiro-de Acosta, Manuel, Fernandez-Clotet, Agnes, de Castro, Luisa, Bosca-Watts, Maia, Casanova, Maria Jose, Lopez-Garcia, Alicia, Lorente, Rufo, Rodriguez, Cristina, Carbajo, Ana Y, Arroyo, Maria Teresa, Gutierrez, Ana, Hinojosa, Joaquin, Martinez-Perez, Teresa, Villoria, Albert, Bermejo, Fernando, Busquets, David, Camps, Blau, Canete, Fiorella, Mancenido, Noemi, Monfort, David, Navarro-Llavat, Merce, Perez-Calle, Jose Lazaro, Ramos, Laura, Rivero, Montserrat, Angueira, Teresa, Camo, Patricia, Carpio, Daniel, Garcia-de-la-Filia, Irene, Gonzalez-Munoza, Carlos, Hernandez, Luis, Huguet, Jose M, Morales, Victor J, Sicilia, Beatriz, Vega, Pablo, Vera, Isabel, Zabana, Yamile, Nos, Pilar, Suarez Alvarez, Patricia, Calvino-Suarez, Cristina, Ricart, Elena, Hernandez, Vicent, Minguez, Miguel, Marquez, Lucia, Hervias Cruz, Daniel, Rubio Iturria, Saioa, Barrio, Jesus, Gargayo-Puyuelo, Carla, Frances, Ruben, Hinojosa, Esther, Del Moral, Maria, Calvet, Xavier, Algaba, Alicia, Aldeguer, Xavier, Guardiola, Jordi, Manosa, Miriam, Pajares, Ramon, Piqueras, Marta, Garcia-Bosch, Orlando, Lopez Serrano, Pilar, Castro, Beatriz, Lucendo, Alfredo J, Montoro, Miguel, Castro Ortiz, Elena, Mesonero, Francisco, Garcia-Planella, Esther, Fuentes, David A, Bort, Inmaculada, Delgado-Guillena, Pedro, Arias, Lara, Iglesias, Agueda, Calvo, Marta, Esteve, Maria, Domenech, Eugeni, Gisbert, Javier P, and Lázaro Pérez-Calle, José

Subjects
durability, real-world evidence, remission, response, ulcerative colitis, ustekinumab
Abstract

The development program (UNIFI) has shown promising results of ustekinumab in ulcerative colitis (UC) treatment that should be confirmed in clinical practice.

Published
2021

10. Long-term outcomes of biologic therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU

Author

Rodriguez-Lago I, Fernandez-Clotet A, Mesonero F, Garcia-Alonso F, Casanova M, Fernandez-de la Varga M, Canete F, de Castro L, Gutierrez A, Sicilia B, Cano V, Merino O, Riestra S, Gonzalez-Partida I, Suris G, Torrealba L, Ferreiro-Iglesias R, Castro B, Marquez L, Sobrino A, Elorza A, Calvet X, Varela P, Betore E, Bujanda L, Lario L, Mancenido N, Garcia-Sepulcre M, Iglesias E, Rodriguez C, Piqueras M, Rosique J, Lucendo A, Benitez O, Garcia M, Olivares D, Gonzalez-Munoza C, Cabriada J, Domenech E, Barreiro-de Acosta N, and ENEIDA Registry

Published
2021

11. Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU

Author

Ferre M, Mesonero E, Florez-Diez P, Gomez C, Fuentes-Valenzuela E, Martin N, Senosiain C, Vela M, Fernandez-Clotet A, Perez P, de Celix C, Calvino-Suarez C, Ferreiro-Iglesias R, Hermida B, Munoz R, Gonzalez-Vivo M, Brunet E, Jimenez N, Botella B, Yebra J, Suarez C, Bouhmidi A, Jurado R, Lopez A, Algarra A, Beso P, Ponferrada A, Plaza R, Duenas C, Benitez J, Soto P, Castillo E, Iyo E, Carbonell-Asins J, Beltran B, and Minguez M

Published
2021

13. Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

Author

Chaparro, M, Garre, A, Mesonero, F, Rodriguez, C, Barreiro-de Acosta, M, Martinez-Cadilla, J, Arroyo, MT, Mancenido, N, Sierra-Ausin, M, Vera-Mendoza, I, Casanova, MJ, Nos, P, Gonzalez-Munoza, C, Martinez, T, Bosca-Watts, M, Busquets, D, Calafat, M, Girona, E, Llao, J, Martin-Arranz, MD, Piqueras, M, Ramos, L, Suis, G, Bermejo, F, Carbajo, AY, Casas-Deza, D, Fernandez-Clotet, A, Garcia, MJ, Ginard, D, Gutierrez-Casbas, A, Hernandez-Villalba, L, Lucendo, AJ, Marquez, L, Merino-Ochoa, O, Rancel, FJ, Taxonera, C, Sanroman, AL, Rubio, S, Domenech, E, and Gisbert, JP

Published
2020

14. Long-term effectiveness of anti-TNF agents in symptomatic stricturing Crohn's disease

Author

Rodriguez-Lago, I, Del Hoyo, J, Casanova, MJ, Fernandez-Clotet, A, Garcia, MJ, Ferreiro-Iglesias, R, Piqueras, M, Suarez, C, Lopez-Garcia, A, Arroyo, M, Sierra, M, Delgado-Guillena, P, Guerra, I, Merino, O, Arranz, L, Llao, J, Plaza, R, Molina, G, Torres, P, Perez-Galindo, P, Herrera-deGuise, C, Armesto, E, Mesonero, F, Aguirre, U, and Gisbert, JP

Published
2020

15. Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry

Author

Colomino, M, Beltran, B, Fernandez-Clotet, A, Flores, E, Navarro, P, Rivero, M, Gutierrez, A, Sierra-Ausin, M, Mesonero, F, Ferreiro-Iglesias, R, Hinojosa, J, Calvet, X, Sicilia, B, Gonzalez-Munoza, C, Antolin, B, Vivo, M, Carbajo, A, Garcia, S, Martin-Cardona, A, Marin, G, Martin-Arranz, M, De Francisco, R, Canete, F, Carlos, T, Gomollon, F, Lorente, R, Rodriguez-Lago, I, Fores-Bosch, A, Bernardos, E, Ramos, L, Delgado, P, Hernandez, A, Van Domselaar, M, Hervas, D, Domenech, E, and Nos, P

Published
2020

16. P471 Predictors of bowel damage in long term progression of Crohn’s disease

Author

A Fernandez Clotet, J Castro Poceiro, Maria Carme Masamunt, Sarai Rodríguez, B Caballol, Elena Ricart, Jordi Rimola, Julià Panés, and Ingrid Ordás

Subjects
medicine.medical_specialty, Crohn's disease, medicine.diagnostic_test, business.industry, Gastroenterology, Magnetic resonance imaging, Ileum, General Medicine, Gold standard (test), medicine.disease, Inflammatory bowel disease, Endoscopy, Term (time), Illness length, medicine.anatomical_structure, Internal medicine, medicine, business
Abstract

Background Crohn’s disease is a chronic inflammatory bowel disorder that progresses to bowel damage over time. An image-based index, the Lémann Index, has been developed to measure the cumulative bowel damage. AIMS To characterize the long-term progression of bowel damage in Crohn’s disease based on changes in the Lémann Index and to determine risk factors for long term progression. Methods This was a single-center longitudinal cohort study. Patients who had participated in prospective studies on the accuracy of magnetic resonance imaging using endoscopy as gold standard and had a follow-up of at least 5 years were reevaluated after 5–12 years. Results Seventy-two patients were included. Lémann Index increased in 38 patients (52.8%), remained unchanged in 9 patients (12.5%) and decreased in 25 patients (34.7%). Small bowel score and surgery subscale significantly increased (p=0.002 and p=0.0001), whereas fistulizing subscale significantly decreased (p=0.001). Baseline parameters associated with bowel damage progression were ileum location (p=0.026), phenotype (stricturing, fistulizing or both with p=0.007, p=0.006 and p=0.035), disease duration >10 years (p=0.019) and baseline Lémann Index stricturing score (p=0.049). No correlation was observed between bowel damage progression and baseline clinical activity, biological markers or endoscopic lesions. Need of surgery during follow-up was a major determinant of bowel damage progression (p=0.0001). Baseline stricturing Lémann Index score was associated with the risk of future surgery (p=0.02). Conclusion Bowel damage, assessed by the Lémann Index, progresses in half of the patients with Crohn’s disease over a period of 5–12 years. The main determinants of bowel damage progression are ileum location, stricturing/fistulizing phenotype and disease duration.

Published
2021
Full Text
View/download PDF

17. Efficacy of a multifactorial strategy for bowel preparation in diabetic patients undergoing colonoscopy: a randomized trial

Author

Miguel A. Pantaleon, Agnes Fernandez-Clotet, Vicente Lorenzo-Zúñiga, Laura Carot, Juan Pedro-Botet, Agustín Seoane, Marco Antonio Alvarez-Gonzalez, Luis Barranco, Agnés Raga, Juana A. Flores-Le Roux, and Felipe Bory

Subjects
Adenoma, Blood Glucose, Dietary Fiber, Male, medicine.medical_specialty, medicine.medical_treatment, Colon cleansing, Colonoscopy, Cecal Neoplasms, Polyethylene Glycols, law.invention, 03 medical and health sciences, 0302 clinical medicine, Patient Education as Topic, Randomized controlled trial, law, Internal medicine, medicine, Humans, Hypoglycemic Agents, Single-Blind Method, Prospective Studies, Prospective cohort study, Intubation, Gastrointestinal, Aged, Diabetis, medicine.diagnostic_test, Performance status, Cathartics, business.industry, Gastroenterology, Colonoscòpia, Diet, Surgery, Regimen, Diabetes Mellitus, Type 2, Tolerability, 030220 oncology & carcinogenesis, Relative risk, Female, 030211 gastroenterology & hepatology, Colorectal Neoplasms, business
Abstract

Background and study aims: Previous studies have reported that diabetes mellitus is an independent risk factor for inadequate bowel preparation. Current guidelines do not recommend a specific preparation for this patient population. The aims of this study were to assess the efficacy, safety, and tolerability of an adapted preparation protocol for colon cleansing in patients with type 2 diabetes mellitus. Patients and methods: This randomized, single-blind, parallel group, superiority trial compared a conventional bowel preparation protocol (CBP) with a diabetes-specific preparation protocol (DSP). The CBP included a low-fiber diet for 3 days followed by a clear liquid diet for 24 hours before colonoscopy. The DSP included a multifactorial strategy combining an educational intervention, a low-fiber diet, and adjustment of blood glucose-lowering agents. All patients received 4 L of a polyethylene glycol solution in a split-dose regimen. The endoscopists were blinded to the preparation protocol. The primary outcome measure was inadequate bowel preparation according to the Boston Bowel Preparation Scale. Secondary outcome measures included hypoglycemic events, tolerability, and acceptability. Results: A total of 150 patients were included in the study (74 CBP and 76 DSP). Both groups were comparable in terms of baseline characteristics. Inadequate bowel cleansing was more frequent following CBP than DSP (20 % vs. 7 %, P = 0.014; risk ratio 3.1, 95 % confidence interval 1.2 – 8). Only CBP and performance status were independently associated with inadequate bowel preparation. Both preparations were equally tolerated and accepted by patients, and side-effects were similar between the groups. Conclusions: A multifactorial strategy for bowel preparation in patients with diabetes undergoing colonoscopy showed a threefold reduction in the rate of inadequate bowel preparation, with no differences in safety and tolerability compared with conventional preparation. Trial registration: ClinicalTrials.gov (NCT02300779).

Published
2016
Full Text
View/download PDF

18. Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)

Author

Sainz Arnau, E., Zabana, Y., Miguel, I., Fernandez Clotet, A., Casanova, M. J., Martin, M. D., Pico, M. D., Alfambra, E., Rodriguez, I., Munoz, F., Dominguez, M., Iglesias, E., Busquets, D., Gutierrez, A., Canete, F., Nunez, L., Taxonera, C., Beltran, B., Camps, B., Calvet, X., Navarro, P., Calafat, M., Ferreiro-Iglesias, R., Gonzalez-Munoza, C., Sicilia, B., Rodriguez, C., Carbajo, A. Y., Domselaar, M., Vicente, R., Piqueras, M., Munoz, M. C., Abad, A., Algaba, A., Martinez, P., Vela, M. I., Antolin, B., Huguet, J. M., Luis Bujanda, Lorente, R. H., Almela, P., Garcia, M. J., Ramirez La Piscina, P., Pajares, R., Perez-Martinez, I., Lucendo, A. J., Merino, O., Legido, J., Vera, I., Morales, V. J., and Esteve, M.

Published
2019

19. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry

Author

Iborra, M, Beltran, B, Fernandez-Clotet, A, Gutierrez, A, Antolin, B, Huguet, J, De Francisco, R, Merino, O, Carpio, D, Garcia-Lopez, S, Mesonero, F, Navarro, P, Ferreiro-Iglesias, R, Carbajo, A, Rivero, M, Gisbert, J, Pinero-Perez, M, Monfort, D, Bujanda, L, Garcia-Sepulcre, M, Martin-Cardona, A, Canete, F, Taxonera, C, Domenech, E, Nos, P, Sierra-Ausin, M, Ferrer-Rosique, J, Martin-Arranz, M, Gonzalez-Munoza, C, Mancenido, N, Rodriguez-Lago, I, Benitez, J, Fores-Bosch, A, Navarro-Llavat, M, Calafat, M, Madrigal-Dominguez, R, Ramos, L, Arroyo, M, Busquets, D, Lorente, R, Sainz-Arnau, E, Hernandez-Camba, A, Morales-Alvarado, V, Paredes, J, Van Domselaar, M, Hervas, D, Canada-Martinez, A, Castro-Poceiro, J, Cameo-Lorenzo, J, Fernandez-Salazar, L, Riestra, S, Casas-Deza, D, Tosca, J, Barrio, J, Garcia, M, Chaparro, M, and GETECCU Grp Grp Espanol Trab

Abstract

Background There are limited data of ustekinumab administered according to the doses recommended in the UNITI studies. Aim To assess the real-world, short-term effectiveness of ustekinumab in refractory Crohn's disease (CD) Methods Multicentre study of CD patients starting ustekinumab after June 2017 at the recommend dose (260, 390 or 520 mg based on weight ~6 mg/kg IV week 0 and 90 mg subcutaneously week 8). Values for Harvey-Bradshaw Index (HBI), C-reactive protein (CRP) and faecal calprotectin (FC) were recorded at baseline and at weeks 8 and 14. Demographic and clinical data, previous treatments, AEs and hospitalisations were documented. Possible predictors of clinical remission were examined. Results Three hundred and five patients were analysed (>= 2 previous anti-TNF alpha therapies 64% and vedolizumab 29%). At baseline, 217 (72%) had an HBI >4 points. Of these, 101 (47%) and 126 (58%) achieved clinical remission at weeks 8 and 14, respectively. FC levels returned to normal (

Published
2019

20. Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU

Author

Rodriguez-Lago, I, Castro-Poceiro, J, Fernandez-Clotet, A, Mesonero, F, Lopez-Sanroman, A, Lopez-Garcia, A, Marquez, L, Clos-Parals, A, Canete, F, Vicuna, M, Nantes, O, Merino, O, Royo, VM, Gordillo, J, Elorza, A, Vicente, R, Casanova, MJ, Ferreiro-Iglesias, R, Perez-Galindo, P, Benitez, JM, Taxonera, C, Garcia, MJ, Arranz, EM, Calafat, M, Martin-Cardona, A, Nunez, FM, Miquel-Cusachs, JO, Arnau, ES, and Gisbert, JP

Published
2019

21. Efficacy and safety of tacrolimus in Crohn's disease: a nationwide, multi-centric study from GETECCU

Author

Rodriguez-Lago, I, Castro-Poceiro, J, Fernandez-Clotet, A, Mesonero, F, Lopez-Sanroman, A, Lopez-Garcia, A, Marquez, L, Clos-Parals, A, Canete, F, Vicuna, M, Nantes, O, Merino, O, Royo, VM, Gordillo, J, Elorza, A, Sanz, P, Casanova, MJ, Ferreiro-Iglesias, R, Perez-Galindo, P, Benitez, JM, Taxonera, C, Garcia, MJG, Arranz, EM, Calafat, M, Martin-Cardona, A, Nunez, FM, Miquel-Cusachs, JO, Arnau, ES, and Gisbert, JP

Published
2019

22. P443 Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)

Author

Isabel Vera, R. Pajares, M. Van Domselaar, R Ferreiro-Iglesias, M Esteve, Beatriz Sicilia, Eva Iglesias, María José Casanova, E Sáinz Arnau, Jesús Legido, Pilar Martínez, P Ramírez de la Piscina, B. Beltrán, R. Vicente, Alicia Algaba, María del Mar Ruiz Domínguez, Luis Bujanda, L Nuñez, M.D. Martín, Fernando Muñoz, B Camps, E Alfambra, Ana Yaiza Carbajo, Victor J. Morales, David Busquets, Carlos Taxonera, I Miguel, M Piqueras, M C Muñoz, Pablo Navarro, Pedro Almela, José María Huguet, Fiorella Cañete, Ismael Rodríguez, M D Picó, Isabel Pérez-Martínez, María Josefa Bernalte García, X. Calvet, Olga Merino, M Calafat, Beatriz Antolín, Agueda Abad, A Fernandez Clotet, Alfredo J. Lucendo, Y Zabana, Cristina Rodríguez, C González-Muñoza, M Vela, Alexandra Gutierrez, and Rufo Lorente

Subjects
medicine.medical_specialty, Crohn's disease, business.industry, Internal medicine, Gastroenterology, Medicine, General Medicine, business, medicine.disease, Upper digestive tract
Published
2019
Full Text
View/download PDF

23. P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn’s disease. Data from clinical practice from the eneida registry

Author

M Mañosa Ciria, A Fernandez-Clotet, A Hernández-Camba, R Muñoz Pérez, M Iborra, M Sierra, L Márquez, P Delgado-Guillena, D Busquets, M Van Domselaar, E Girona, E Sánchez-Rodríguez, M D Martín-Arranz, R Lorente, D Casas-Deza, M Boscá, F Cañete, M Calafat, and E Domènech

Subjects
Gastroenterology, General Medicine
Abstract

Background Anti-TNF and thiopurines are the only drugs that demonstrated efficacy in preventing postoperative recurrence (POR) in Crohn’s disease (CD). However, in some cases these drugs are contraindicated or have previously failed. Recently, ustekinumab was licensed for CD but no data on its efficacy in the prevention of POR is still available. Methods All CD patients in whom ustekinumab was prescribed for primary prevention of POR within the first 3 months after ileocecal or ileocolonic resection with anastomosis were identified from the ENEIDA registry (a prospectively maintained database of the Spanish Working Group in IBD –GETECCU-). We evaluated the rates of endoscopic, clinical or surgical POR in the first 18 months. Endoscopic POR was defined by a Rutgeerts score >i1 and advanced endoscopic POR by >i2. Results Thirty patients were included; ustekinumab was started after a median time of 60 days (IIQ 31–90). Concomitant immunosuppressants were used in 17%, 27% received an additional 3-month course of metronidazole after surgery. Regarding risk factors for POR: 23% were active smokers, 62% had prior resections, 33% had penetrating CD behaviour, and 22% had a history of perianal disease. In total, 36% of them had more than one risk factor. 50% had been exposed to ustekinumab prior to the index surgery (46% within the last 6 months). The median time of follow-up on ustekinumab was 17 months (IQR 11–21). Fifty-six per cent of patients had at least one endoscopic assessment within 18 months after surgery: 58% had endoscopic POR and 23% advanced endoscopic POR. Additionally, 13% presented clinical POR at the discretion of the treating physician and none developed surgical POR. Conclusion In a small clinical practice cohort, ustekinumab showed similar efficacy as that reported with anti-TNF in the prevention of endoscopic POR. Unfortunately, the lack of early endoscopic monitoring is still frequent despite the recommendations from guidelines.

Published
2020
Full Text
View/download PDF

24. Mo1860 REAL-WORLD LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY

Author

Iborra, Marisa, Beltran, Belen, Fernández-Clotet, Agnes, Flores, Eva Iglesias, Cortes, Pablo Navarro, Rivero, Montserrat, Gutiérrez, Ana, Sierra-Ausin, Monica, Mesonero, Francisco, Ferreiro, Rocio, Hinojosa, Joaquin, Calvet, Xavier, Sicilia, Beatriz, González-Muñosa, Carlos, Antolín, Beatriz, Gonzalez, Maria, López, Ana Y. Carbajo, García-López, Santiago, Cardona, Albert Martin, Surís, Gerard, Arranz, Maria Dolores A. Martín, De Francisco, Ruth M., Cañete, Fiorella, Samso, Carlos Taxonera, Gomollon, Fernando, Lorente, Rufo, Rodríguez-Lago, Iago, Fores-Bosh, Ana, Bernardos, Esther, Ramos, Laura, Delgado-Guillena, Pedro, Camba, Alejandro Hernandez, Van Domselaar, Manuel, Hervás, David, Domènech, Eugeni, and Nos, Pilar

Published
2020
Full Text
View/download PDF

25. Su1865 – Real-World Short-Term Effectivenes of Ustekinumab in Crohn’s Disease: Results from the Eneida Registry

Author

Iborra, Marisa, Beltran, Belen, Fernández-Clotet, Agnes, Gutiérrez, Ana, Antolín, Beatriz, Huguet, José María, de Francisco, Ruth, Merino-Ochoa, Olga, Carpio, Daniel, García-López, Santiago, Mesonero, Francisco, Mínguez, Miguel, Ferreiro, Rocio, López, Ana Y. Carbajo, Rivero, Montserrat, Chaparro, María, Piñero-Pérez, M. Concepción, Miquel, David Monfort i, Bujanda, Luis, García-Sepulcre, Mariana Fe, Cardona, Albert Martin, Cañete, Fiorella, Taxonera, Carlos, Sierra-Ausin, Monica, Ferrer-Rosique, Juan A., Martín-Arranz, MD, González-Muñosa, Carlos, Marcos, Noemí Manceñido, Rodríguez-Lago, Iago, Flores, Eva Iglesias, Fores-Bosh, Ana, Navarro-Llavat, Merce, Calafat, Margalida, Madrigal-Domínguez, Rosa E., Ramos, Laura, Arroyo, Maite, Busquets, David, Lorente, Rufo, Sainz-Arnau, Empar, Camba, Alejandro Hernandez, Morales, Victor Jair, Paredes, Jose María, Van Domselaar, Manuel, Hervás, David, Cañada, Antonio, and Nos, Pilar

Published
2019
Full Text
View/download PDF

26. REAL-WORLD SHORT-TERM EFFECTIVENES OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY

Author

Iborra, Marisa, Beltran, Belen, Fernandez-Clotet, Agnes, Gutierrez, Ana, Antolin, Beatriz, Huguet, Jose Maria, Francisco, Ruth, Merino-Ochoa, Olga, Carpio, Daniel, Garcia-Lopez, Santiago, Mesonero, Francisco, Minguez, Miguel, Ferreiro, Rocio, Lopez, Ana Y. Carbajo, Rivero, Montserrat, Chaparro, Maria, Pinero-Perez, M. Concepcion, Monfort I Miquel, David, Luis Bujanda, Garcia-Sepulcre, Mariana Fe, Cardona, Albert Martin, Canete, Fiorella, Taxonera, Carlos, Sierra-Ausin, Monica, Ferrer-Rosique, Juan A., Martin-Arranz, M. D., Gonzalez-Munosa, Carlos, Marcos, Noemi Mancenido, Rodriguez-Lago, Iago, Flores, Eva Iglesias, Fores-Bosh, Ana, Navarro-Llavat, Merce, Calafat, Margalida, Madrigal-Dominguez, Rosa E., Ramos, Laura, Arroyo, Maite, Busquets, David, Lorente, Rufo, Sainz-Arnau, Empar, Camba, Alejandro Hernandez, Morales, Victor Jair, Paredes, Jose Maria, Domselaar, Manuel, Hervas, David, Canada, Antonio, and Nos, Pilar

27. Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu

Author

García, M. J., Rivero, M., Miranda-Bautista, J., Bastón-Rey, I., Mesonero, F., Leo-Carnerero, E., Casas-Deza, D., Cagigas Fernández, C., Martin-Cardona, A., El Hajra, I., Hernández-Aretxabaleta, N., Pérez-Martínez, I., Fuentes-Valenzuela, E., Jiménez, N., Rubin de Célix, C., Gutiérrez, A., Suárez Ferrer, C., Huguet, J. M., Fernández-Clotet, A., González-Vivó, M., Del Val, B., Castro-Poceiro, J., Melcarne, L., Dueñas, C., Izquierdo, M., Monfort, D., Bouhmidi, A., Ramírez de la Piscina, P., Romero, E., Molina, G., Zorrilla, J., Calvino-Suárez, C., Sánchez, E., Núñez, A., Sierra, O., Castro, B., Zabana, Y., González-Partida, I., De la Maza, S., Castaño, A., Nájera-Muñoz, R., Sánchez-Guillén, L., Riat Castro, M., Rueda, J. L., Benítez, J. M., Delgado-Guillena, P., Tardillo, C., Peña, E., Frago-Larramona, S., Rodríguez-Grau. M. C., Plaza, R., Pérez-Galindo, P., Martínez-Cadilla, J., Menchén, L., Barreiro-De Acosta, M., Sánchez-Aldehuelo, R., De la Cruz, M. D., Lamuela, L. J., Marín, I., Nieto-García, L., López San Román, A., Herrera, J. M., Chaparro, M., Gisbert, J. P., Young Group of GETECCU, [García MJ, Rivero M] Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain. [Miranda-Bautista J] Gastroenterology Department, Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), and Departamento de Medicina, Universidad Complutense, Madrid, Spain. [Bastón-Rey I] Gastroenterology Department, Hospital Universitario Clínico de Santiago, Santiago de Compostela, Spain. [Mesonero F] Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Leo-Carnerero E] Gastroenterology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Delgado-Guillena P] Gastroenterology Department, Hospital General de Granollers, Granollers, Spain, Hospital General de Granollers, [Jose Garcia, Maria] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Rivero, Montserrat] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Castro, Beatriz] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Miranda-Bautista, Jose] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Menchen, Luis] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Marin, Ignacio] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Miranda-Bautista, Jose] Univ Complutense, Dept Med, Madrid 28009, Spain, [Menchen, Luis] Univ Complutense, Dept Med, Madrid 28009, Spain, [Marin, Ignacio] Univ Complutense, Dept Med, Madrid 28009, Spain, [Baston-Rey, Iria] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Calvino-Suarez, Cristina] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Barreiro-De Acosta, Manuel] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Nieto-Garcia, Laura] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Mesonero, Francisco] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Sanchez, Eugenia] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Sanchez-Aldehuelo, Ruben] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Lopez-San Roman, Antonio] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Leo-Carnerero, Eduardo] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Nunez, Andrea] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Dolores De la Cruz, Maria] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Manuel Herrera, Jose] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Casas-Deza, Diego] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Sierra, Olivia] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Javier Lamuela, Luis] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Cagigas Fernandez, Carmen] Hosp Univ Marques de Valdecilla, Dept Gen & Digest Surg, Colorectal Unit, Santander 39008, Spain, [Martin-Cardona, Albert] Hosp Univ Mutua Terrassa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol Dept, Terrassa 08221, Spain, [Zabana, Yamile] Hosp Univ Mutua Terrassa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol Dept, Terrassa 08221, Spain, [El Hajra, Ismael] Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda 28220, Spain, [Gonzalez-Partida, Irene] Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda 28220, Spain, [Hernandez-Aretxabaleta, Nerea] Hosp Univ Basurto, Gastroenterol Dept, Bilbao 48013, Spain, [De la Maza, Saioa] Hosp Univ Basurto, Gastroenterol Dept, Bilbao 48013, Spain, [Perez-Martinez, Isabel] Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA 33, Dept Gastroenterol, Oviedo 33011, Spain, [Castano, Andres] Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA 33, Dept Gastroenterol, Oviedo 33011, Spain, [Fuentes-Valenzuela, Esteban] Hosp Univ Rio Hortega, Gastroenterol Dept, Valladolid 47012, Spain, [Najera-Munoz, Rodrigo] Hosp Univ Rio Hortega, Gastroenterol Dept, Valladolid 47012, Spain, [Jimenez, Nuria] Hosp Gen Univ Elche, Gastroenterol Dept, Alicante 03203, Spain, [Rubin de Celix, Cristina] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Castro, Micaela Riat] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Chaparro, Maria] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Gisbert, Javier P.] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Gutierrez, Ana] Hosp Gen Alicante, Gastroenterol Dept, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante 03010, Spain, [Suarez Ferrer, Cristina] Hosp Univ La Paz, Gastroenterol Dept, Madrid 28046, Spain, [Luis Rueda, Jose] Hosp Univ La Paz, Gastroenterol Dept, Madrid 28046, Spain, [Maria Huguet, Jose] Hosp Gen Univ Valencia, Gastroenterol Dept, Valencia 46014, Spain, [Fernandez-Clotet, Agnes] Hosp Clin Barcelona, Gastroenterol Dept, Barcelona 08036, Spain, [Gonzalez-Vivo, Maria] Hosp del Mar, Gastroenterol Dept, Barcelona 08003, Spain, [Del Val, Blanca] Hosp Rafael Mendez, Gastroenterol Dept, Lorca 30817, Spain, [Castro-Poceiro, Jesus] Hosp St Joan Despi Moises Broggi, Gastroenterol Dept, Barcelona 08970, Spain, [Melcarne, Luigi] Hosp Univ Parc Tauli, Gastroenterol Dept, Sabadell, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona 08208, Spain, [Duenas, Carmen] Hosp Univ Caceres, Gastroenterol Dept, Caceres 10003, Spain, [Izquierdo, Marta] Hosp Univ Cabuenes, Gastroenterol Dept, Gijon 33203, Spain, [Monfort, David] Consorcio Sanitario Terrasa, Gastroenterol Dept, Barcelona 08227, Spain, [Bouhmidi, Abdel] Hosp Santa Barbara, Gastroenterol Dept, Puertollano 13500, Spain, [Ramirez De la Piscina, Patricia] Hosp Univ Vitoria Gasteiz, Gastroenterol Dept, Vitoria 01002, Spain, [Romero, Eva] Hosp Clin Univ Valencia, Gastroenterol Dept, Valencia 46010, Spain, [Molina, Gema] Hosp Arquitecto Marcide, Gastroenterol Dept, Ferrol 15405, Spain, [Zorrilla, Jaime] Hosp Univ Gregorio Maranon, Dept Colorectal & Gastrointestinal Surg, Madrid 28009, Spain, [Sanchez-Guillen, Luis] Hosp Gen Univ Elche, Dept Colorectal & Gastrointestinal Surg, Alicante 03203, Spain, [Manuel Benitez, Jose] Hosp Reina Sofia, Gastroenterol Dept, IMIBIC, Cordoba 14004, Spain, [Delgado-Guillena, Pedro] Hosp Gen Granollers, Gastroenterol Dept, Granollers 08042, Spain, [Tardillo, Carlos] Hosp Nuestra Sanora de la Candelaria, Gastroenterol Dept, Tenerife 38010, Spain, [Pena, Elena] Hosp Royo Villanova, Gastroenterol Dept, Zaragoza 50007, Spain, [Frago-Larramona, Santiago] Complejo Hosp Soria, Gastroenterol Dept, Soria 42005, Spain, [Carmen Rodriguez-Grau, Maria] Hosp Univ Henares, Gastroenterol Dept, Coslada 28002, Spain, [Plaza, Rocio] Hosp Univ Infanta Leonor, Gastroenterol Dept, Madrid 28031, Spain, [Perez-Galindo, Pablo] Complejo Hosp Univ Pontevedra, Gastroenterol Dept, Pontevedra 36071, Spain, [Martinez-Cadilla, Jesus] Hosp Alvaro Cunqueiro Vigo, Gastroenterol Dept, Vigo 36312, Spain, and Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU)

Subjects
Gastroenterología y hepatología, Crohn’s disease, vedolizumab, medicine.medical_specialty, Crohns-disease, Cirurgia - Complicacions, Surgical complications, Productes biològics, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES], Outcomes, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Postoperative Complications [DISEASES], Crohn, Malaltia de, Lower risk, Inflammatory bowel disease, Article, ustekinumab, Vedolizumab, surgery, inflammatory bowel disease, Internal medicine, Ustekinumab, postoperative complications, Medicine, Risk factor, ulcerative colitis, Crohn's disease, preoperative therapy, business.industry, Postoperative infectious complications, Retrospective cohort study, General Medicine, anti-TNF, Metaanalysis, medicine.disease, Resection, mezclas complejas::productos biológicos [COMPUESTOS QUÍMICOS Y DROGAS], Ulcerative colitis, afecciones patológicas, signos y síntomas::procesos patológicos::complicaciones posoperatorias [ENFERMEDADES], Gastrointestinal surgery, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES], Risk-factors, Ulcerative-colitis, Preoperative steroid use, Complex Mixtures::Biological Products [CHEMICALS AND DRUGS], business, medicine.drug
Abstract

Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered “exposed”. The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5, 95% CI: 1.2–2.0), urgent surgery (OR: 1.6, 95% CI: 1.2–2.2), laparotomy approach (OR: 1.5, 95% CI: 1.1–1.9) and severe anaemia (OR: 1.8, 95% CI: 1.3–2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2, 95% CI: 0.97–1.58), although it could be a risk factor for postoperative infections (OR 1.5, 95% CI: 1.03–2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results